Autologous stem-cell transplantation for solid tumors in adults.
Over the last decade, high-dose chemotherapy (HDC) with autologous stem-cell transplantation has been explored for a variety of solid tumors in adults, particularly breast cancer, ovarian cancer, and nonseminomatous germ-cell tumors. Response of phase II studies are encouraging in most cases, and, in certain settings, seem clearly superior to historical results of conventional-dose chemotherapy. The value of HDC for adult solid tumors is a highly controversial issue, currently being addressed in large randomized phase II trials. This article reviews the results of HDC in different diseases and depicts potential directions of future progress.
Nieto
Y
Y
University of Colorado Bone Marrow Transplant Program, Denver, USA. yxnieto@entente.uhcolorado.edu
Shpall
E J
EJ
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000628:therapy; D005260:Female; D018237:Germinoma / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000628:therapy; D012008:Recurrence; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents